• Pexidartinib: Designing Better TAM Assays

  2026-09-24

  Pexidartinib (PLX3397) offers a way to perturb CSF1R signaling, but interpreting macrophage responses requires more than counting cells. This article connects its research use to a distinct SPP1-focused study and outlines assay choices that separate receptor inhibition from changes in tumor-associated myeloid-cell state.

• Levofloxacin: Assay Workflows and Research Uses

  2026-09-24

  Levofloxacin connects bacterial DNA gyrase inhibition assays with practical investigations of osteoblast and cartilage biology. This guide translates its reported properties into reproducible workflows, solvent controls, and troubleshooting strategies—while distinguishing exploratory research from clinical interpretation.

• BIBR 1532: Separating Telomerase Block from Telomere Damage

  2026-09-23

  BIBR 1532 is a selective telomerase inhibitor for studying hTERT, telomere maintenance, and cancer-cell responses. This article explains how to distinguish direct telomerase inhibition from telomere loss caused by replication stress, using recent CF10–EdU findings to sharpen assay interpretation.

• Metformin Attenuates Vocal Fold Fibrosis via AMPK

  2026-09-23

  A 2025 study reports that metformin reduced collagen deposition and profibrotic signaling in rabbit vocal fold injury and TGF-β1-stimulated fibroblast models. Its findings connect AMPK activation with suppression of the TGF-β/Smad axis, while also highlighting the need for dose, delivery, and functional voice studies before clinical translation.

• Regorafenib (BAY 73-4506) Assay Guide

  2026-09-22

  A scenario-based guide to using Regorafenib (BAY 73-4506), SKU A8236, in viability, proliferation, migration, and signaling studies. It connects practical assay design with quantitative kinase, melanoma, formulation, and storage data to support more interpretable cancer biology research.

• BOP Reagent for Peptide and Prodrug Workflows

  2026-09-22

  BOP reagent offers a practical route to carboxyl group activation, amide bond formation, and phenyl ester preparation in peptide and prodrug research. This guide connects reaction setup and troubleshooting with assay decisions inspired by a carrier-free, ROS-responsive oral cancer prodrug study.

• Anisomycin Workflows for JNK and Apoptosis

  2026-09-21

  Anisomycin provides a practical JNK agonist workflow for connecting early stress-signaling events with later apoptosis phenotypes. This guide combines cancer-cell assay design with a carefully bounded interpretation of the reference study on Neuroligin 1 proteolysis and social-memory maintenance.

• Galectin-1, FIP200, and Autophagy in NAFLD

  2026-09-21

  A 2026 study identifies a direct Galectin-1–FIP200 interaction as an upstream brake on hepatic autophagy, linking this mechanism to steatosis, dyslipidemia, and insulin resistance. Its combination of mouse gain-of-function models, proteomic profiling, binding analysis, and interaction-disrupting mutations provides a mechanistic framework for metabolic liver disease research.

• NFIA Coordinates Bone Remodeling and Bone Mass

  2026-09-20

  The reference study identifies NFIA as a previously underappreciated regulator of bone homeostasis that acts in mesenchymal and osteoprogenitor compartments to coordinate osteoclast, osteoblast, and adipocyte differentiation. Its findings show that NFIA suppresses both bone resorption and formation, but loss of its antiresorptive activity has the stronger net effect, producing impaired bone mass accrual.

• Chloroquine Diphosphate: Reading Autophagy in HBV Models

  2026-09-19

  Chloroquine Diphosphate is more informative when used to distinguish autophagosome accumulation from completed autophagic flux. This article connects A8628 assay design with a 2025 HBV study showing how HBsAg redirects TBK1 signaling between interferon production and autophagy.

• Recombinant Human FGF-19: Practical Workflow

  2026-09-18

  This dossier-based guide explains how to reconstitute, qualify, and apply Recombinant Human FGF-19 in FGFR4 binding, cell proliferation, and metabolic regulation research. It is intended for controlled in vitro workflows and should not be treated as evidence for efficacy in animals, patients, or disease-specific models without independent validation.

• Gly-Gly-Phe-Gly: Designing Better Assays

  2026-09-18

  Gly-Gly-Phe-Gly (GGFG) is examined as a modular peptide linker and an experimental variable, not merely a passive spacer. This article connects GGFG peptide design with mechanism-focused assay logic inspired by panobinostat research in MLL-rearranged leukemia.

• ATP Solution for mRNA and Kinase Workflows

  2026-09-17

  Build more reproducible kinase, transcription, ligation, and phosphorylation assays with a ready-to-use 100 mM ATP stock. This workflow-focused guide connects ATP control to the upstream preparation and validation of mRNA-LNP studies, including localized p21 replacement research.

• Pollen Interference in EEM Hazardous-Substance Detection

  2026-09-17

  Zhang et al. show that pollen fluorescence can confound hazardous-bioaerosol classification, but targeted spectral preprocessing and fast Fourier transform (FFT) features can substantially improve random-forest recognition. The study reached 89.24% accuracy across 31 sample types and clearly separated several bacterial and toxin targets, supporting more robust fluorescence-based screening.

• KU-55933: Selective ATM Kinase Inhibitor Workflows

  2026-09-16

  KU-55933 enables controlled interrogation of ATM signaling across DNA damage response, Akt phosphorylation, cell-cycle, and metabolic assays. This workflow-focused guide explains how to formulate the compound, establish concentration and time windows, and connect mitochondrial stress findings with testable ATM-dependent phenotypes.

645 records 1/43 page Next 12345 下5页 Last page